What is the recommended dose of Vitamin K for newborns in India?

The NNF and IAP recommend intramuscular Vitamin K1 (phytomenadione) 1 mg for all term neonates and 0.5 mg for preterm neonates weighing less than 1500 grams, administered within the first hour of birth to prevent Vitamin K Deficiency Bleeding (VKDB).

Why is Vitamin K given to all newborns at birth?

Newborns have very low stores of Vitamin K at birth because it does not cross the placenta efficiently and the neonatal gut is sterile, lacking Vitamin K-producing bacteria. Without prophylaxis, neonates are at risk of VKDB, which can cause life-threatening intracranial hemorrhage.

Is oral Vitamin K as effective as the intramuscular injection?

Oral Vitamin K is less reliable than the intramuscular route. While oral protocols exist (2 mg at birth, repeated at 1 week and 4-6 weeks), they require multiple doses and compliance is difficult to ensure. The NNF recommends IM injection as the preferred route in India due to higher efficacy and single-dose convenience.

What are the types of Vitamin K Deficiency Bleeding in neonates?

VKDB is classified into three types: early (within 24 hours, often due to maternal medications), classical (days 2-7, presenting as GI or umbilical bleeding), and late (2 weeks to 6 months, often presenting as intracranial hemorrhage). Intramuscular Vitamin K effectively prevents all three forms.

Are there any side effects of Vitamin K injection in newborns?

Vitamin K injection is extremely safe. The most common side effect is mild pain and swelling at the injection site. Rare allergic reactions have been reported. The earlier concern about a possible association with childhood cancer has been thoroughly disproven by large epidemiological studies.

Vitamin K Injection Newborn: NNF Guidelines India

Introduction to Vitamin K Prophylaxis in Newborns

Vitamin K deficiency bleeding (VKDB), formerly known as hemorrhagic disease of the newborn, remains a significant but entirely preventable cause of neonatal morbidity and mortality worldwide. In India, where approximately 25 million births occur annually, universal Vitamin K prophylaxis at birth is one of the most cost-effective interventions available in neonatal care. The National Neonatology Forum (NNF) of India, in alignment with the Indian Academy of Pediatrics (IAP) and the World Health Organization (WHO), strongly recommends administering Vitamin K1 (phytomenadione) to every newborn within the first hour of life.

Despite the strength of evidence and simplicity of implementation, Vitamin K prophylaxis coverage in India remains suboptimal, particularly in home deliveries, rural areas, and lower-tier healthcare facilities. Understanding the pharmacology of Vitamin K in neonates, the classification and risk factors for VKDB, and the specific dosing protocols endorsed by Indian guidelines is essential for every healthcare provider involved in newborn care.

Pharmacology of Vitamin K in Neonates

Vitamin K is a fat-soluble vitamin essential for the hepatic synthesis of coagulation factors II (prothrombin), VII, IX, and X, as well as anticoagulant proteins C and S. Neonates are uniquely vulnerable to Vitamin K deficiency for several physiological reasons.

Why Neonates Are Deficient

Poor placental transfer: Vitamin K1 crosses the placenta poorly, resulting in cord blood levels that are only 10 to 30 percent of maternal levels.
Low hepatic stores: Neonatal liver stores of Vitamin K are extremely limited at birth.
Sterile gut: The neonatal intestine lacks the bacterial flora (particularly Bacteroides and Escherichia coli) that synthesize Vitamin K2 (menaquinone) in older children and adults. Colonization takes several days to weeks.
Low content in breast milk: Human breast milk contains only 1 to 4 micrograms per litre of Vitamin K, which is substantially lower than infant formula (approximately 50 to 60 micrograms per litre).
Immature hepatic function: The neonatal liver has reduced capacity to utilize available Vitamin K for carboxylation of clotting factor precursors.

Pharmacokinetics After Intramuscular Administration

When administered intramuscularly, Vitamin K1 acts as a depot injection. Peak plasma levels are achieved within 2 to 4 hours. The intramuscular route provides sustained release over days to weeks, maintaining adequate coagulation factor levels during the vulnerable neonatal period. The half-life of phytomenadione is approximately 1.5 to 3 hours in neonates, but the depot effect of IM injection ensures prolonged protection. Hepatic metabolism occurs via the cytochrome P450 system, and excretion is primarily through bile and urine.

Classification of Vitamin K Deficiency Bleeding

VKDB is classified into three distinct forms based on the timing of onset, each with characteristic clinical features and risk factors.

Type	Onset	Common Sites	Risk Factors	Prevention
Early VKDB	Within 24 hours	Cephalohematoma, intracranial, intrathoracic	Maternal drugs: anticonvulsants (phenytoin, carbamazepine), warfarin, rifampicin, isoniazid	Maternal Vitamin K supplementation in last month; neonatal IM Vitamin K
Classical VKDB	Day 2 to 7	GI tract, umbilical stump, circumcision site, skin	Inadequate Vitamin K prophylaxis, exclusive breastfeeding without supplementation	IM Vitamin K at birth
Late VKDB	2 weeks to 6 months	Intracranial (50-80%), skin, GI tract	Exclusive breastfeeding, cholestatic liver disease, malabsorption syndromes, no prophylaxis	IM Vitamin K at birth; oral regimen if IM unavailable

Late VKDB is the most devastating form, with intracranial hemorrhage occurring in 50 to 80 percent of cases, carrying a mortality rate of 20 percent and a long-term neurological morbidity rate exceeding 50 percent in survivors. In the Indian context, late VKDB is disproportionately seen in exclusively breastfed infants who did not receive prophylaxis at birth, highlighting the critical importance of universal coverage.

NNF and IAP Dosing Guidelines

The NNF Essential Newborn Care guidelines and IAP recommendations provide clear dosing protocols for Vitamin K prophylaxis in Indian neonates.

Intramuscular Route (Preferred)

Category	Dose	Route	Timing
Term neonates (BW ≥ 1500 g)	1 mg	Intramuscular (anterolateral thigh)	Within 1 hour of birth
Preterm neonates (BW < 1500 g)	0.5 mg	Intramuscular (anterolateral thigh)	Within 1 hour of birth
Extremely preterm (< 1000 g)	0.3 mg/kg	Intramuscular	Within 1 hour of birth

Oral Route (When IM Not Feasible)

In situations where intramuscular injection is not available, such as home deliveries in rural India, an oral regimen may be considered. The NNF recommends oral Vitamin K1 at a dose of 2 mg at birth, repeated at 3 to 5 days, and again at 4 to 6 weeks of age. However, this requires strict adherence to all three doses, which is often difficult to ensure in community settings. The oral route does not prevent late VKDB as effectively as the intramuscular route.

Special Considerations for Indian Practice

Government hospital settings: Many district hospitals and community health centres in India now include Vitamin K prophylaxis as part of their essential newborn care package under the National Health Mission. The Navjaat Shishu Suraksha Karyakram (NSSK) training program includes Vitamin K administration as a key component.
Private hospitals: Most private hospitals and nursing homes in urban India administer IM Vitamin K as standard practice in the delivery room or operating theatre.
Home deliveries: An estimated 20 to 25 percent of Indian births still occur at home, particularly in states like Uttar Pradesh, Bihar, and Madhya Pradesh. ASHA workers and ANMs (Auxiliary Nurse Midwives) are being trained to administer or refer for Vitamin K prophylaxis.
Formulation availability: Vitamin K1 injection (phytomenadione) is available in India in 1 mg/0.5 mL and 10 mg/mL ampoules. The 1 mg preparation is preferred for neonatal use to avoid dosing errors.

International Guideline Comparison

The Indian NNF recommendations are broadly aligned with international guidelines. The AAP (American Academy of Pediatrics) recommends a single IM dose of 0.5 to 1 mg for all newborns. The NICE (National Institute for Health and Care Excellence) guidelines in the United Kingdom recommend 1 mg IM at birth, with an oral alternative of 2 mg at birth, 1 week, and 1 month. The WHO recommends 1 mg IM at birth for all newborns as part of essential newborn care, emphasizing this intervention for low-resource settings.

Administration Technique and Practical Considerations

Injection Technique

Clean the anterolateral aspect of the mid-thigh with an alcohol swab.
Use a 25-gauge needle, 16 mm length for term neonates.
Administer the injection at a 90-degree angle into the vastus lateralis muscle.
Do not aspirate before injection (current WHO recommendation).
Apply gentle pressure after withdrawal; do not massage the site.

Storage and Handling

Vitamin K1 injection must be stored between 2 and 8 degrees Celsius, protected from light, as it degrades with UV exposure. In Indian NICUs and delivery rooms, maintaining cold chain integrity is essential. Once the ampoule is opened, it should be used immediately and any unused portion discarded. Multi-dose vials should not be used for neonates due to infection risk.

Contraindications and Safety Profile

Vitamin K1 injection has an excellent safety profile with very few contraindications. Known hypersensitivity to phytomenadione or any excipient in the formulation is the only absolute contraindication. The preparation should be used with caution in neonates with severe hepatic impairment, though this does not represent a contraindication. The earlier controversy regarding a possible association between intramuscular Vitamin K and childhood leukemia, first raised by Golding et al. in 1992, has been conclusively refuted by multiple large cohort studies and meta-analyses.

Monitoring and Documentation

Administration of Vitamin K should be documented in the newborn's medical record, the mother's discharge summary, and the immunization card. In facilities using the HEAMAC neonatal care documentation system, Vitamin K administration status can be tracked as part of essential newborn care protocols, ensuring no infant is missed. Healthcare providers should also assess and document any signs of bleeding in the first week of life, including oozing from the umbilical stump, blood in stools, or unexpected bruising.

Cost-Effectiveness in the Indian Context

Vitamin K prophylaxis is one of the most cost-effective interventions in neonatal care. The cost of a single ampoule of Vitamin K1 in India ranges from INR 5 to INR 25, depending on the manufacturer. Compared with the cost of treating a single case of late VKDB with intracranial hemorrhage (which may require neurosurgery, blood products, and prolonged NICU admission costing INR 2 to 10 lakhs), universal prophylaxis represents an extraordinary return on investment. The Indian Journal of Pediatrics has published multiple analyses confirming the cost-effectiveness of universal IM Vitamin K prophylaxis even in low-resource settings.

Clinical Pearl: Every newborn, regardless of birth setting, gestational age, or feeding method, should receive Vitamin K prophylaxis at birth. The intramuscular route is preferred in all healthcare facility births. Oral Vitamin K should only be considered when IM injection is truly not feasible, with clear documentation and follow-up plans for repeat dosing.

Conclusion

Vitamin K prophylaxis at birth is a simple, safe, and highly effective intervention that prevents a potentially catastrophic bleeding disorder. In India, achieving universal coverage remains a public health priority that requires continued training, supply chain strengthening, and community awareness. Every healthcare provider attending a delivery should ensure that Vitamin K is administered as part of essential newborn care, contributing to the national goal of reducing preventable neonatal deaths.

Vitamin K Prophylaxis in Newborns: Indian NNF Guidelines & Dosing Protocol